Options
2015
Journal Article
Titel
QIAD assay for quantitating a compound's efficacy in elimination of toxic Av oligomers
Abstract
Strong evidence exists for a central role of amyloid beta-protein (A beta) oligomers in the pathogenesis of Alzheimer's disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the A beta aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZA beta 3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on A beta aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer's disease.
Author(s)